Background
==========

The skin is an attractive target for gene therapy protocols for cutaneous diseases, vaccines and several metabolic disorders because it is easily accessible for both delivery and monitoring. To fully take advantage of skin as a target for gene transfer, it is important to establish an efficient and reproducible delivery system. Electroporation as a tool for the delivery of plasmid DNA is a strong candidate to meet these delivery criteria. Electroporation-mediated cutaneous plasmid DNA delivery has been demonstrated by many groups \[[@B1],[@B2]\] for the eventual purpose of gene therapy.

Liposome or vesicle-complexed plasmid DNA has also been tested for enhancing transgene expression in the skin. Topical delivery has been performed in intact skin \[[@B3]-[@B9]\] and skin stripped of keratinocytes \[[@B10]-[@B12]\]. Intradermal injection of liposomes has been performed in a rat skin flap model \[[@B13]\]. This delivery may induce an immune response and has therefore been tested in vaccine delivery \[[@B8]-[@B11]\] and delivery has also been performed for therapeutic purposes \[[@B3],[@B10],[@B13]\]. In the study presented here, reporter expression was observed after intradermal injection of liposome-complexed DNA alone and in combination with *in vivo*electroporation.

Electroporation (EP) is a physical method that enhances delivery of molecules to tissues *in vivo*. Confined electrical pulses are delivered to tissues at levels which increase cell permeability without killing the cells, enabling molecules to pass through the cell membrane. EP has been used to effectively deliver chemotherapeutic agents to tumors in animals and in humans \[[@B14]\] and plasmid DNA to a variety of tissues in both animals and humans \[[@B1]\].

Recent studies have shown that electroporation efficiently delivers plasmid DNA to the skin resulting in increased local and serum expression levels compared to injection alone \[[@B15]-[@B31]\]. Skin electroporation delivery has been successfully performed in rodent \[[@B15],[@B16],[@B18]-[@B22],[@B24],[@B26]-[@B32]\], rabbit \[[@B25]\], pig \[[@B16],[@B17],[@B23],[@B32]\] and non-human primate \[[@B16],[@B32]\] model systems.

Several studies have been designed to use electrically mediated plasmid delivery for vaccine purposes, including hepatitis B surface antigen \[[@B17],[@B22],[@B23],[@B25]\] and HIV \[[@B32]\]. Electrically mediated plasmid delivery to the skin has also been tested therapeutically. Delivery of the gene encoding erythropoietin to the skin achieved significantly elevated serum levels as well as significantly elevated hematocrit compared to injection of plasmid without EP \[[@B18]\]. Delivery of a plasmid encoding a growth factor \[[@B24],[@B28]\] or a transcription factor which controls growth factor expression \[[@B31]\] increased wound healing. These studies demonstrate the feasibility of using this approach therapeutically or for increasing serum levels of a specific protein.

Molecule delivery is more efficient when the field is applied in more than one direction \[[@B33]-[@B35]\]. With two plate electrodes, the electrode must be repositioned for the second set of pulses. Therefore, a non-invasive four-plate electrode (4PE) was developed to allow the application of two sets of pulses rotated 90° with respect to each other, which makes pulse application more straightforward \[[@B29]\]. Delivery with this electrode results in reporter gene expression equivalent or superior to commercially available electrodes for delivery to the skin. The purpose of the experiments described here is to further investigate localized cutaneous plasmid delivery with the 4PE. Localized transgene expression levels and kinetics and histological damage were compared after the electrically mediated delivery of plasmid DNA. Delivery with the electrode was also tested in a larger rodent model, the rat.

Methods
=======

Animals
-------

Six to 7 week old female BALB/c mice (NCI) or 200--250 gram male Sprague Dawley rats were anesthetized in an induction chamber charged with 3% isoflurane in O~2~then fitted with a standard rodent mask and kept under general anesthesia during treatment.

Plasmid delivery
----------------

gWizLuc was commercially prepared (Aldevron, Fargo, ND). Endotoxin levels were \< 0.1 EU/μg plasmid. For *in vivo*electroporation, 50 μl gWizLuc suspended to 2 μg/μl in sterile injectable saline was injected intradermally. Using a 4PE electrode \[[@B29]\], eight 100 V/cm 150 ms pulses at a frequency of 1 Hz were immediately applied with a BTX 830 pulse generator (BTX Molecular Delivery Systems, Holliston, MA) unless otherwise noted. For liposome delivery, 100 μg gWizLuc was complexed with a commercial preparation of DOTAP (*N*-\[1-(2,3-dioleoyloxy) propyl\]-*N,N,N*-trimethyl-ammonium-methyl-sulfate, (Roche Diagnostics, Mannheim, Germany) in a ratio of 1:1.6 (w/w) \[[@B10]\] and 50 μl was injected intradermally.

Luciferase reporter assay
-------------------------

At the indicated time points after plasmid delivery, luciferase activity was quantified as previously described \[[@B36]\]. The treated area was consistently 6 mm in diameter. However, since there was some variation in the diametric tissue excised, activity was expressed in total ng luciferase per treatment area. Values represent mean and standard error. Experiments containing only two groups were analyzed by Student\'s unpaired T test. Experiments with greater than two groups were analyzed by nonparametric ANOVA.

Histological analysis
---------------------

For histological analysis, 50 μl 2 μg/μl gWizLuc was delivered using eight 150 ms 100 V/cm pulses with the 4PE. At the time points indicated, the mice were euthanized and a seven mm diameter circle of skin 2--3 mm thick that encompassed the 6 mm diameter treatment area was removed. After fixation in 10% neutral buffered formalin for six hours, each sample was dehydrated in ascending grades of ethanol, cleared in xylene, and infiltrated with paraffin. Following embedding, tissues were cut into four 4 mm sections. Sections were stained with hematoxylin and eosin and then examined histologically for damage. Samples were graded using a schema including surface damage, inflammation, bullae, muscle degeneration and subepidermal necrosis in eight 4 × 7 mm sections \[[@B29]\]. For surface damage, the percentage of each section damaged was determined. For the other damage assessments, any damage seen within a low power field (40×), even focal points, was considered positive. The percentage reported was the number of positive fields seen (eight fields per section and four sections per sample). The total amount of damage was determined for each sample and expressed as the mean and SEM of the percentage of the total treatment area. Significance was determined for the three groups by nonparametric ANOVA.

Results and discussion
======================

EP delivery previously optimized in mouse skin was directly compared to liposome-based delivery (Figure [1](#F1){ref-type="fig"}). At 48 hours, the DNA:DOTAP formulation tested tended to increase reporter expression. EP increased expression significantly, nearly 20 fold higher than the liposome formulation. When EP and liposome delivery were combined, expression was not significantly higher than injection alone. The combination of liposome delivery and *in vivo*electroporation for plasmid delivery has been compared in previous studies. Wells, *et al*. found no difference in transgene expression after delivery of a luciferase encoding plasmid by electroporation with six 1 ms 800--1600 V/cm pulses, with small unilamellar DOTAP lipoplexes, or with the combination to MC2 mouse mammary tumors \[[@B37]\]. Cemazar, et al. found that transfection efficiency of a plasmid encoding green fluorescent protein was more effective in complex with lipofectin than naked plasmid DNA injection when delivered to several mouse tumor types. However, electrically mediated delivery of plasmid alone using eight 5 ms 600 V/cm pulses significantly increased transfection. The combination of complexed DNA and electroporation was not significantly different from electroporation alone \[[@B38]\].

![**Comparison of liposome and EP delivery of plasmid DNA**. Luciferase expression in mouse skin 48 hours after delivery of 100 μg gWizLuc as described in materials and methods. Inj, injection only, n = 12; Lip, liposomes, n = 12; Electroporation, EP, n = 12; Lip+EP, liposomes + EP, n = 4. \*\*\*p \< 0.001 with respect to injection only; \*p \< 0.05 with respect to liposomes.](1479-0556-6-16-1){#F1}

There are several possible reasons as to why the results of these three studies differ considerably. There are variations the lipid composition, the reporter gene delivered, the *in vivo*electroporation parameters, and the method of analysis (overall transgene expression vs. transfection efficiency). In addition, these studies used a tumor, rather than skin, model. Tumor cells typically divide more rapidly than skin cells. It is understood that both EP and liposomes can destabilize cell membranes and, in this particular case, perhaps the combination of the two is disruptive, leading to decreased cell survival and ultimately decreased expression. Alternatively, exposure of the liposomes to EP may release the DNA prior to contact with the membranes and reduce the transport of plasmid through the cell membrane which would also lead to reduced transgene expression.

Clearly, EP enhances skin expression after intradermal injection of plasmid DNA \[[@B15]-[@B23],[@B25],[@B26],[@B29]\]. After a single cutaneous delivery, significantly increased reporter expression has been demonstrated in rabbits for two days \[[@B25]\], in mice \[[@B27]\] and rats \[[@B18],[@B19],[@B26]\] to seven days, and in mice to approximately two weeks \[[@B22],[@B29]\]. The differences in levels and duration of expression may be due to the different models, plasmid constructs, electrodes, electroporation protocols, and methods of analysis used.

In an attempt to increase the duration of transgene expression, multiple deliveries were performed. Two delivery time courses were tested, day 0 followed by days 2 and 4 (Figure [2](#F2){ref-type="fig"}), and day 0 followed by days 10 and 20 (Figure [3](#F3){ref-type="fig"}). With deliveries at days 0, 2, and 4 (Figure [2](#F2){ref-type="fig"}), expression spiked 48 hours after the first delivery at 5.4 ± 1.4 total ng luciferase, similar to the levels observed previously \[[@B29]\]. This expression significantly decreased on days 4 and 6. Expression significantly peaked again at day 11 at 6.6 ± 1.9 total ng luciferase. This is possibly related to when the skin tissue recovered from any damage produced by the EP process. Multiple deliveries did not significantly increase the duration of transgene expression. This agrees with Lin, *et al*., who observed that two deliveries 24 hours apart did not result in increased luciferase expression \[[@B28]\] in a rat model.

![**Duration and levels of skin luciferase expression after delivery of plasmid by EP on days 0, 2, and 4**. Luciferase expression in mouse skin after delivery of 100 μg gWizLuc at days 0, 2, 4, 6, 11, 18, and 26 as described in materials and methods. n = 12. \*p \< 0.05 with respect to injection only at the specified time point.](1479-0556-6-16-2){#F2}

![**Duration and levels of skin luciferase expression after delivery of plasmid by EP on days 0, 10, and 20**. Luciferase expression in mouse skin after delivery of 100 μg gWizLuc at days 0, 2, 10, 12, 17, 20, 22, 30, 37, and 42 as described in materials and methods. n = 12. \*p \< 0.05 with respect to injection only at the specified time point.](1479-0556-6-16-3){#F3}

When deliveries were performed on days 0, 10, 20, a similar immediate increase in reporter expression to 5.7 ± 1.9 total ng luciferase was observed (Figure [3](#F3){ref-type="fig"}). Interestingly, no spike in expression was observed after the day 10 delivery. However, day 12 expression was significantly higher than injection alone. A small but insignificant spike in expression was observed 48 hours after the day 20 delivery, and a statistically significant difference was also observed at day 37. Similar to the first time course, these multiple deliveries did not significantly alter the time course of reporter expression from that of a single plasmid delivery \[[@B29]\].

In this study, only a small increase in expression duration is observed with either multiple treatment protocol. Skin cell turnover time for mice is approximately 7--12 days. If tissue trauma due to EP were limiting expression, cell turnover should allow subsequent peaks in expression. Cell turnover may not facilitate increased expression with the short interval delivery, but with the second delivery time course, one would expect long-term increased expression especially following delivery at 20 days. For these reasons, histological analysis of the delivery site was performed (Table [1](#T1){ref-type="table"}, Table [2](#T2){ref-type="table"}). For both of these experiments, the second and third deliveries were performed at the same specific site as the initial delivery, since repeat procedures at the same site might negatively impact cellular integrity and reduce expression.

###### 

Tissue damage after three deliveries on days 0, 2, and 4.

                              **DNA+EP-**   **DNA-EP+**      **DNA+EP+**
  --------------------------- ------------- ---------------- -----------------
  **Surface Damage**                                         
                                                             
  **Day 4**                   1.3 ± 0.5     14.2 ± 4.4\*\*   9.5 ± 3.5
  **Day 6**                   2.4 ± 1.9     11.0 ± 3.0\*\*   10.7 ± 3.0\*
                                                             
  **Inflammation**                                           
                                                             
  **Day 4**                   68.1 ± 12.7   100 ± 0          75.0 ± 11.5
  **Day 6**                   66.7 ± 11.2   95.8 ± 4.2       59.7 ± 10.3
                                                             
  **Bullae**                                                 
                                                             
  **Day 4**                   4.2 ± 4.2     47.2 ± 11.2\*    43.1 ± 13.7
  **Day 6**                   4.2 ± 4.2     37.5 ± 6.5\*     52.7 ± 13.1\*\*
                                                             
  **Muscle Degeneration**                                    
                                                             
  **Day 4**                   59.7 ± 12.0   97.9 ± 2.1\*     72.2 ± 11.3
  **Day 6**                   66.7 ± 9.4    95.8 ± 4.2       52.8 ± 11.6
                                                             
  **Subepidermal Necrosis**                                  
                                                             
  **Day 4**                   8.3 ± 5.6     48.6 ± 10.7\*    43.8 ± 13.8
  **Day 6**                   12.5 ± 9.0    50.0 ± 10.7\*    40.3 ± 13.5

Values represent the mean and SEM for three independent experiments (n = 4) for a total of 12 samples.

DNA, gWizLuc

EP, electroporation

\*\*p \< 0.01

\*p \< 0.05

###### 

Tissue damage after three deliveries on days 0, 10, and 20.

                              **DNA+EP-**    **DNA-EP+**      **DNA+EP+**
  --------------------------- -------------- ---------------- -------------
  **Surface Damage**                                          
                                                              
  **Day 12**                  2.4 ± 0.9      0.5 ± 0.2        3.0 ± 1.2
  **Day 22**                  3.8 ± 1.1      0.3 ± 0.2\*      3.0 ± 1.1
                                                              
  **Inflammation**                                            
                                                              
  **Day 12**                  68.0 ± 12.7    68.0 ± 9.3       95.8 ± 4.2
  **Day 22**                  52.6 ± 11.8    95.8 ± 4.2\*\*   77.8 ± 6.9
                                                              
  **Bullae**                                                  
                                                              
  **Day 12**                  31.9 ± 14.1    8.3 ± 5.6        29.2 ± 13.2
  **Day 22**                  12.7 ± 5.9     4.2 ± 4.2        23.6 ± 9.5
                                                              
  **Muscle Degeneration**                                     
                                                              
  **Day 12**                  68.0 ± 12.7    48.6 ± 10.7      84.7 ± 9.0
  **Day 22**                  55.1 ± 11.2    66.7 ± 11.2      79.2 ± 7.7
                                                              
  **Subepidermal Necrosis**                                   
                                                              
  **Day 12**                  23.6 ± 12.88   12.5 ± 8.5       38.9 ± 14.1
  **Day 22**                  25.9 ± 8.8     4.2 ± 4.2        16.7 ± 9.4

Values represent the mean and SEM for three independent experiments (n = 4) for a total of 12 samples.

DNA, gWizLuc

EP, electroporation

\*\*p \< 0.01

\*p \< 0.05

After deliveries on days 0, 2, and 4, EP significantly increased surface damage, bullae, and subdermal necrosis over plasmid injection alone at both 4 and 6 days (Table [1](#T1){ref-type="table"}). This damage may be ameliorated by the presence of plasmid DNA. No delivery type significantly increased inflammation more than any other. At day 4, muscle degeneration was increased significantly over plasmid injection alone, but this degeneration was resolved by day 6.

In the longer time course, deliveries were performed at days 0, 10, and 20, while histological analysis was performed at days 12 and 22 (Table [2](#T2){ref-type="table"}). In this time course, low levels of surface damage were observed, although a significant increase with EP alone was observed over plasmid injection alone at day 22. Inflammation was also increased with EP alone at this time point. No significant differences were observed between delivery types in bullae, muscle degeneration, or subepidermal necrosis.

Although damage is observed in each time course following the second delivery, this damage does not increase after the third delivery. While there were no obvious safety issues with repeat deliveries, the results presented here suggest that repeat administrations should not be performed at the same specific site.

It was important to demonstrate that plasmid delivery with the 4PE would increase skin transgene expression in a larger model with thicker skin, the rat. Pulses of 100 V/cm and 150 ms resulted in the highest expression levels in the mouse \[[@B29]\]. In mouse skin, 20 ms pulses of 100 or 200 V/cm pulses increased expression to approximately 60% of 100 V/cm 150 ms. However, in the study described here, while several pulse types resulted in significantly higher reporter expression (Figure [4](#F4){ref-type="fig"}), a longer or higher field strength pulse was necessary for the higher levels of expression rat skin. This may reflect the differences in skin architecture between the two models. While many EP protocols may increase transgene expression in multiple models, some protocol optimization is necessary based on skin structure and thickness.

![**EP delivery of plasmid DNA to rat skin**. Luciferase expression in skin 48 hours after delivery of 100 μg gWizLuc with eight pulses at the conditions noted. n = 12. \*\*\*p \< 0.001 with respect to injection only; \*\*p \< 0.01 with respect to injection only; \*p \< 0.05 with respect to injection only.](1479-0556-6-16-4){#F4}

Conclusion
==========

Electroporation is an effective method for *in vivo*delivery of plasmid DNA \[[@B1],[@B2]\], and this approach is also an effective tool for cutaneous applications. As has been seen with other tissues, a variety of EP protocols ranging from short, high field strength to long, low field strength pulses as well as both invasive and surface electrodes have been tested. When developing a protocol for a skin based application, it is important to consider all of these variables as each will contribute to the levels and duration of expression obtained. Expression levels in response to delivery of plasmids encoding potentially toxic molecules such as cytokines should be tightly controlled with only short term expression. Expression after delivery of plasmids encoding potential vaccine candidates also may only require short-term expression. However, in the case of replacement of a defective protein such as Factor IX, long-term expression is desirable.

The results obtained in the current study demonstrated that a non-invasive surface electrode can be used to deliver plasmid DNA to the skin. Delivery was successful in both mice and rats. The highest expression levels in each species were obtained with different EP parameters. While this delivery method is safe, if an application is being developed that requires multiple administrations, it is advisable to not perform the repeat at the same exact site as the first administration. As has been seen with delivery to other tissues, EP is a safe and reliable method to obtain efficient and effective delivery of plasmid DNA.
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